Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria
MetadataShow full item record
AuthorTriviño Ibáñez, Eva María; Sánchez-Vañó, Raquel; Sopena Novales, Pablo; Romero Fábrega, Juan Carlos; Rodríguez Fernández, Antonio; Carnero Pardo, Cristóbal; Martínez Lozano, María Dolores; Gómez Río, Manuel
Wolters Kluwer Health, Inc
Alzheimer’s diseaseAppropriate use criteriaAmyloid PETMild cognitive impairmentFlorbetaben PET
Triviño-Ibáñez, E. M., Sánchez-Vañó, R., Sopena-Novales, P., Romero-Fábrega, J. C., Rodríguez-Fernández, A., Pardo, C. C., ... & Gómez-Río, M. (2019). Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria. Medicine, 98(29).
To evaluate the use of amyloid-positron emission tomography (PET) in routine clinical practice, in a selected population with cognitive impairment that meets appropriate use criteria (AUC). A multicenter, observational, prospective case-series study of 211patients from 2 level-3 hospitals who fulfilled clinical AUC for amyloid-PET scan in a naturalistic setting. Certainty degree was evaluated using a 5-point Likert scale: 0 (very low probability); 1 (low probability); 2 (intermediate probability); 3 (high probability); and 4 (practically sure), before and after amyloid PET. The treatment plan was considered as cognition-specific or noncognition-specific. Amyloid-PET was positive in 118 patients (55.9%) and negative in 93 patients (44.1%). Diagnostic prescan confidence according amyloid-PET results showed that in both, negative and positive-PET subgroup, the most frequent category was intermediate probability (45.7% and 55.1%, respectively). After the amyloid-PET, the diagnostic confidence showed a very different distribution, that was, in the negative-PET group the most frequent categories are very unlikely (70.7%) and unlikely (29.3%), while in the positive- PET group were very probable (57.6%) and practically sure (39%). Only in 14/211 patients (6.6%) the result of the amyloid-PET did not influence the diagnostic confidence, while in 194 patients (93.4%), the diagnostic confidence improved significantly after amyloid- PET results. The therapeutic intention was modified in 93 patients (44.1%). Specific treatment for Alzheimer disease was started, before amyloid-PET, in 80 patients (37.9%). This naturalistic study provides evidence that the implementation of amyloid-PET is associated with a significant improvement in diagnostic confidence and has a high impact on the therapeutic management of patients with mild cognitive impairment fulfilled clinical AUC.